Chui, M. H., Kjaer, S. K., Frederiksen, K., Hannibal, C. G., Wang, T., Vang, R., & Shih, I. (2019). BRAF(V600E)-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma. Oncotarget.
Citação norma ChicagoChui, M. Herman, Susanne K. Kjaer, Kirsten Frederiksen, Charlotte G. Hannibal, Tian-Li Wang, Russell Vang, and Ie-Ming Shih. "BRAF(V600E)-mutated Ovarian Serous Borderline Tumors Are At Relatively Low Risk for Progression to Serous Carcinoma." Oncotarget 2019.
Citação norma MLAChui, M. Herman, et al. "BRAF(V600E)-mutated Ovarian Serous Borderline Tumors Are At Relatively Low Risk for Progression to Serous Carcinoma." Oncotarget 2019.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.